Benzinga | Oct 15, 2020 11:43AM EDT

B of A Securities Maintains Buy on Esperion Therapeutics, Lowers Price Target to $52

B of A Securities maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $55 to $52.